Treatment of Patients with Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review of Economic Evaluations
-
Published:2022-12
Issue:6
Volume:20
Page:594-602
-
ISSN:1558-7673
-
Container-title:Clinical Genitourinary Cancer
-
language:en
-
Short-container-title:Clinical Genitourinary Cancer
Author:
Pelloux-Prayer Rémi,
Bataillard Thomas,
Thiery-Vuillemin Antoine,
Vincent Alexandre,
Fagnoni Philippe,
Nerich VirginieORCID
Reference47 articles.
1. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study;Fitzmaurice;JAMA Oncol,2018
2. Cancer Statistics, 2021;Siegel;CA Cancer J Clin,2021
3. Management of metastatic hormone-sensitive prostate cancer (mHSPC): an evolving treatment paradigm;Weiner;Curr Treat Options Oncol,2019
4. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer;Sweeney;N Engl J Med,2015
5. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial;James;Lancet Lond Engl,2016
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献